As of June 3, 2025, Immunovia AB (publ) (IMMNOV.ST) reports a Net Margin of -8221.37%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Immunovia AB (publ)'s Net Margin
Over recent years, Immunovia AB (publ)'s Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -8221.37% |
| 2023-12-31 | -19646.92% |
| 2022-12-31 | -14680.52% |
| 2021-12-31 | -18479.38% |
| 2020-12-31 | -40340.61% |
This slight downward trend highlights how Immunovia AB (publ) manages its overall profitability and cost control over time.
Comparing Immunovia AB (publ)'s Net Margin to Peers
To better understand Immunovia AB (publ)'s position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Immunovia AB (publ) (IMMNOV.ST) | -8221.37% |
| Titan Medical Inc (TMD.TO) | 39.43% |
| Sectra AB (SECT B.ST) | 24.83% |
| CellaVision AB (CEVI.ST) | 19.46% |
| NanoRepro AG (NN6.DE) | 18.27% |
| Surgical Science Sweden AB (SUS.ST) | 14.89% |
Compared to its competitors, Immunovia AB (publ)'s Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.